WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES

Checking

 

Zimmer Biomet Holdings, Inc. ZBH

NYSEMedical devicesFinancials to Sep 30, 2026 · Updated Nov 11, 2026

On Stock Analysis · affiliate link
ZBH financials
Moat score
53
ROIC
5.3%
P/E
26.5
EV/EBIT
23.6
FCF yield
5.7%
Dividend yield
0.9%
Market cap
$20.3B

Moat ranks

Score rankTied #347 of 396
Durabilitymedium
Market structureOligopoly
Pricing powerweak

Balance sheet

9/30/26
$BDec 31Sep 30
Cash0.60.4
Securities0.00.0
Debt7.57.5
Net cash-6.9-7.1
Equity12.712.7
Leverage
Debt / EBITDA
3.31×
Debt / equity
0.59×
Leases (12/31/25)
$233M
Capital
Diluted shares
191M
Book value / share
$66.43
Price / book
1.6×
Net cash / share
−$37.12
Market cap
$20.3B
Enterprise value
$27.4B

Per-share record

Fiscal years and TTM
Scale
$0$20$40$60'16'17'18'19'20'21'22'23'2441.43'2544.78TTM
Revenue per shareCash flow per share

Key indicators

Latest: Q3 '26
IndicatorLatestVs year agoLast 8 quarters
Revenue growth3.1%-6.6 pts
Operating margin14.9%-2.6 pts
FCF margin16.8%+3.5 pts
Capex / revenue10.3%+2.8 pts
Knee implant sales per quarter$768M-3%
Hip implant sales per quarter$537M+6%
S.E.T. sales per quarter$578M+7%
Selling price effect–-1%
Knee implant sales · 12/31/25$3.3B+5%

Margins and growth from reported quarters; company KPIs as reported in results releases.

About ZBH

Zimmer Biomet sells joint-replacement implants, sports medicine, extremity and trauma devices, plus robotic, digital and surgical support products. Knees account for about 40% of 2025 sales; hips and S.E.T. each contribute roughly a quarter.

Revenue mix
Knees 40.4%S.E.T. (Sports Medicine, Extremities, Trauma, CMFT) 26.1%Hips 25.4%Technology & Data, Bone Cement and Surgical 8.1%
  • Design In Qualification

    Knee systems require product-specific technique, instruments, training, and OR familiarity.

  • Service Field Network

    Consignment-heavy inventory and local clinical support improve case readiness and responsiveness.

  • Design In Qualification

    Hip systems are embedded in procedure-specific technique and instrument workflows, creating moderate retraining and qualification friction.

  • Service Field Network

    Local field coverage and consigned inventory support case readiness and responsiveness, but no category-specific service retention, response-time, or margin evidence establishes a strong advantage over incumbent peers.

Timeline
  1. Sep 8, 2026

    Zimmer Biomet announced new Americas and portfolio leadership, with promotions effective October 1 and Kevin Thornal departing September 30; it reaffirmed the August outlook while seeking faster U.S. commercial execution.

  2. Sep 2, 2026

    A federal court denied Zimmer’s effort to end the Morrison hip-implant claims at the pleadings stage and allowed a fraud amendment; the case remains a litigation risk and the ruling sets no damages amount.

  3. Aug 28, 2026

    A federal court granted Zimmer summary judgment in the McMillan hip-implant case and ordered it closed; this resolves that case, not the wider product-liability portfolio.

  4. Aug 5, 2026

    Zimmer Biomet raised 2026 reported sales-growth guidance to 3.9%–4.9% and organic constant-currency guidance to 2.25%–3.25% after Q2 results; acquired sales and currencies still contribute to the gap.

  5. Apr 28, 2026

    CFO Suketu Upadhyay departed and Paul Stellato became interim CFO, creating a finance-leadership transition while the company integrates acquisitions and changes its U.S. sales model.

Financial record

Fiscal year2016201720182019202020212022202320242025TTMTrendChange 2016–25
Per share ($)
Revenue37.8938.3138.9833.6729.6032.4533.0035.2637.6641.4344.78+1.0%/yr
Cash flow8.067.778.596.725.206.676.457.547.358.549.85+0.6%/yr
Earnings1.518.90-1.865.41-0.052.121.384.884.433.554.01+9.9%/yr
Free cash flow5.445.356.433.493.404.654.334.174.435.646.05+0.4%/yr
Capex2.622.422.163.231.792.022.123.372.932.913.79+1.2%/yr
Dividends0.930.950.960.950.960.950.960.960.960.960.98+0.3%/yr
Book value47.7757.6155.3959.9358.9160.1757.1659.5261.1563.9066.43+3.3%/yr
Diluted shares (M)202204204207207210210210204199191-0.2%/yr
Totals ($B)
Revenue7.77.87.97.06.16.86.97.47.78.28.6+0.8%/yr
Operating income0.80.80.01.10.10.90.71.31.31.11.2+3.3%/yr
Net income0.31.8-0.41.1-0.00.40.31.00.90.70.8+9.7%/yr
Free cash flow1.11.11.30.70.71.00.90.90.91.11.2+0.2%/yr
Buybacks0.40.00.00.00.00.00.10.70.90.50.8+1.8%/yr
Dividends0.20.20.20.20.20.20.20.20.20.20.2+0.1%/yr
Net cash-10.6-9.6-8.4-7.6-7.3-6.6-5.3-5.4-5.7-6.9-7.1+$3.7B
Margins & returns (%)
Gross margin61.664.963.864.961.963.563.364.263.861.661.9+0.1 pts
Operating margin10.710.20.416.01.412.610.017.316.713.313.6+2.6 pts
Net margin4.023.2-4.816.1-0.26.54.213.811.88.69.0+4.6 pts
FCF margin14.414.016.510.411.514.313.111.811.813.613.5-0.8 pts
ROIC3.63.40.25.00.44.03.66.46.45.05.3+1.4 pts
Return on equity3.215.5-3.49.0-0.13.52.48.27.25.66.0+2.4 pts
R&D % of revenue4.84.74.95.75.36.45.96.25.75.65.0+0.8 pts
Stock pay % of revenue0.70.70.81.11.21.11.51.31.31.11.1+0.3 pts
Capex % of revenue6.96.35.59.66.16.26.49.67.87.08.5+0.1 pts

Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.

TTM = four quarters to Sep 30, 2026. Per-share values use diluted weighted shares.ROIC = operating income × (1 − 10.1% tax rate, the company's own over three fiscal years excluding one-offs) ÷ (equity + debt − cash and current securities). Returns show a dash when their base is negative or under 10% of revenue. Free cash flow = operating cash flow − capex. Debt is all borrowings; net cash counts long-term securities and excludes leases.

Moat

Moat scorecard

Moat score53
Strength
Confidence
Structure
Oligopoly
Durability
medium
Trajectory
narrowing
Pricing power
weak
Segments
  • Knees40.4%
    2 claims
  • Hips25.4%
    2 claims
  • S.E.T. (Sports Medicine, Extremities, Trauma, CMFT)26.1%
    1 claim
  • Technology & Data, Bone Cement and Surgical8.1%
    No moat

Moat claims

Applies to
Knees
Confidence
Durability
medium
Trajectory
narrowingas of Sep 30, 2026
Why it holds

Knee systems require product-specific technique, instruments, training, and OR familiarity. The filing identifies entrenched clinical practice as an adoption barrier, supporting moderate qualification friction, but surgeons can retrain and large health systems can standardize vendors.

Why narrowing

Q3 knee sales declined 3.1% reported and 2.6% in constant currency, reflecting competitive pressure and the sales-channel transition. Surgeon training and product qualification have not prevented the setback.

Indicators
  • Knee implant sales$3.3B+5%
  • Knee implant sales per quarter$768M-3%
  • Selling price effect–-1%
Risks
  • Hospital standardization reduces surgeon choice
  • New implant designs narrow differentiation
  • Shift of volume to price-sensitive ambulatory surgery centers

Profile change log

  1. Oct 8, 2026 · business change

    Zimmer Biomet announced new Americas and portfolio leadership, with promotions effective October 1 and Kevin Thornal departing September 30; it reaffirmed the August outlook while seeking faster U.S. commercial execution.

  2. Oct 8, 2026 · business change

    A federal court denied Zimmer’s effort to end the Morrison hip-implant claims at the pleadings stage and allowed a fraud amendment; the case remains a litigation risk and the ruling sets no damages amount.

  3. Oct 8, 2026 · business change

    A federal court granted Zimmer summary judgment in the McMillan hip-implant case and ordered it closed; this resolves that case, not the wider product-liability portfolio.

  4. Oct 8, 2026 · business change

    Zimmer Biomet raised 2026 reported sales-growth guidance to 3.9%–4.9% and organic constant-currency guidance to 2.25%–3.25% after Q2 results; acquired sales and currencies still contribute to the gap.

  5. Oct 8, 2026 · business change

    CFO Suketu Upadhyay departed and Paul Stellato became interim CFO, creating a finance-leadership transition while the company integrates acquisitions and changes its U.S. sales model.

  6. Oct 8, 2026 · business change

    Zimmer Biomet bought Monogram, adding CT-based robotic knee technology with commercialization using Zimmer implants expected by early 2027; the acquisition adds development and execution risk before recurring revenue is proved.

  7. Oct 8, 2026 · business change

    Zimmer Biomet completed the Paragon 28 acquisition, adding a foot-and-ankle portfolio and sales force; acquired growth, integration costs and low goodwill headroom now need to be tested against cash returns.

  8. Oct 8, 2026 · business change

    Zimmer Biomet spun off ZimVie’s spine and dental businesses, concentrating the remaining company on joint reconstruction and related orthopedic products.

  9. Oct 8, 2026 · analyst revision

    Updated knee share from 30.1% in 2023 to an industry estimate of 29.6% in 2025 and retained the earlier estimate. Classified the mixed technology/cement/surgical category as competitive because rival platforms and separate consumable economics do not establish an oligopoly across the whole category.

  10. Oct 8, 2026 · analyst revision

    Changed product revenue weights from Q2 2026 to FY2025: knees 40.36%, hips 25.43%, S.E.T. 26.12% and technology/cement/surgical 8.09%. Added trajectories, management, debate and linked market profiles. The original five claim scores and verified-no-moat status remain; newer industry share estimates support narrowing knee protection.

Industry & peers

Peer map

0%10%20%30%40%50%60708090100Moat scoreIndustry medianZBHMDTISRG

Hover a point for its values; click a peer to compare. Dashed lines: industry medians.

Global knee reconstruction

As of Oct 8, 2026
OligopolyLow cyclicalityUSD 10B in 2023

Implants, instruments and surgical-assistance systems used to replace or revise failed knee joints worldwide. Excludes other joints, spine implants and general soft-tissue surgery.

ZBH 30.1%SYK 22.5%JNJ 14.4%SNNOthers 24%
StocksMoatGross m.Op. m.
ZBH5361.9%13.6%
Industry median147552.1%13.3%
Sector median557661.5%17.3%
All stocks median3987653.1%20.0%

Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.

Drivers & risks

Demand drivers
  • Ageing populations and osteoarthritis support replacement demand; the main limit is treatment access and surgical capacity.
  • Movement to outpatient surgery and ambulatory centers changes inventory, instrument and service needs and creates demand for faster procedures.
  • Robotics, navigation and improved implant designs can win surgeon adoption and redirect share among established vendors.
Risks
  • Hospital purchasing groups, reimbursement limits and government tenders restrict price increases despite clinical preference.
  • Staff shortages and elective-procedure deferrals can delay sales even when patients still need surgery.
  • Device recalls, liability claims and stricter quality requirements can damage trust and disrupt supply.
  • Currency swings, tariffs and higher manufacturing costs affect multinational suppliers; rates also affect hospitals’ robotic capital budgets.

Bulls & bears

Key question · as of Nov 11, 2026

Can product launches and the U.S. sales-channel overhaul stop knee share loss and convert acquired growth into durable organic growth and cash generation?

Arguments

4 forFaded: weakening or settled4 against

What to watch

  1. 1Knee and hip sales against peer and market growth, using like-for-like currency and acquisition definitions
  2. 2Selling-price effect and instrument/inventory investment needed to support case coverage
  3. 3Operating cash flow, acquired-business performance, debt and foot-and-ankle goodwill headroom

Next check: Q4 and FY2026 results: test knee recovery, channel retention, pricing and acquired-business cash returns. Monitor foot-and-ankle impairment headroom and legal proceedings. A results date is not confirmed.

Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.

Cite or reuse this data

Free to reuse, commercially too, with a credit link. See the data license.

Moat Score 53/100 by <a href="https://www.findmymoat.com/stocks/XNYS:ZBH">Find My Moat</a> (as of September 2026)

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.